Lunch Workshop: Cell and Gene Therapies: The Path Ahead

***THIS SESSION NOW TAKING PLACE IN THE COMMERCIALISING FUTURE THERAPIES TRACK ROOM***

In this workshop we will explore where cell and gene therapy manufacturing is now — and where it must go next — to enhance global access to these life-changing therapies. Embracing the opportunities ahead, we will highlight solutions to some of the major challenges in making autologous CAR T cell therapies and AAV-based gene therapies. Production costs per dose are very high, as these therapeutics are highly personalized and largely do not benefit from economies of scale. Furthermore, current manufacturing processes lack robustness and suffer from batch failures or delays in release. One reason is that these novel therapeutics do not yet benefit from the highly standardized, optimized, modular, and flexible platform processes that are routine for more established modalities such as monoclonal antibodies. Join us to learn how, together, we can redefine manufacturing of these modern medicines to improve more patients’ lives.

WHAT TO EXPECT

Part 1: This workshop will highlight some of the innovations that will drive cell and gene therapy towards standardized platform processes and technology. Together, let’s:

• Explore the changing dynamics of cell and gene therapy manufacturing
• Embrace the challenges opportunities ahead
• Learn how to simplify AAV production while enhancing both robustness and quality — with a novel cell line development portfolio
• Discover how to reduce cost, improve speed, and minimize variability of cell therapies — with a next-generation automated manufacturing platform developed as part of a collaboration with Kite, a Gilead Company.

Part 2: In an interactive Q&A, the expert panel will answer your questions on the progress of the field and how to overcome challenges in adopting new technologies

Workshop joined by:

Emmanuelle Cameau, Strategic Technology Partnership Leader, Cytiva

Volker Huppert, Chief Development Officer, GlycoStem

Heather Main, Project Manager, ATMP Sweden

Kyle Zingaro, Head of Gene Therapy Process Sciences, UCB

Sven Kili, Chief Development Officer, CCRM